Top 20 Companies in the Global Chronic Idiopathic Constipation Market (2025-2035): Expert View by Spherical Insights
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, the Global Chronic Idiopathic Constipation Market Size is projected to grow from USD 6.28 Billion in 2024 to USD 12.05 Billion by 2035, at a CAGR of 6.1% during the forecast period 2025–2035. Global market expansion is driven by rising cases of chronic idiopathic constipation, growing awareness, an ageing population, technological advancement, and demand for over-the-counter solutions.
Introduction
The rising incidence of chronic idiopathic constipation is a pivotal driver for the chronic idiopathic constipation market. The condition affects a large segment of the population, which shows increased occurrence among senior citizens. The combination of demographic changes and unhealthy lifestyle choices which include poor eating habits and inactivity, is responsible for the rising number of patients. As more people understand gastrointestinal health, they start looking for medical treatment, thus creating a need for effective solutions. The systematic review discovered that approximately 18.9 percent of worldwide older adults who are 60 years and above suffer from constipation, which shows different prevalence rates depending on the region and the diagnostic criteria used. The Chronic Idiopathic Constipation Market experiences substantial growth because of pharmaceutical research innovations which create new market opportunities. Recent advancements in drug formulation and delivery technology have resulted in new treatment methods which address the fundamental causes of constipation. The market is seeing increasing interest in treatments that either boost gastrointestinal movement or change gut bacteria. People want treatment methods which they can easily obtain without needing to see a doctor. Younger individuals show a strong preference for handling their personal health issues without outside assistance. The OTC segment is expected to grow as manufacturers introduce a variety of supplements aimed at alleviating constipation symptoms.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Chronic Idiopathic Constipation Market.
Chronic Idiopathic Constipation Market Size & Statistics
- The Market Size for Chronic Idiopathic Constipation Was Estimated to be worth USD 6.28 Billion in 2024.
- The Market Size is Going to Expand at a CAGR of 6.1% between 2025 and 2035.
- The Global Chronic Idiopathic Constipation Market Size is anticipated to reach USD 3.1 Billion by 2035.
- North America is estimated to dominate the market during the forecast period in the Chronic Idiopathic Constipation Market.
- Asia-Pacific is projected to grow the fastest during the forecast period in the Chronic Idiopathic Constipation Market.
Market Segmentation
Global Chronic Idiopathic Constipation Market Size, Share, By Diagnosis (Blood Tests, Sigmoidoscopy, Colonoscopy, Balloon Expulsion Test, Anorectal Manometry), By User (Hospitals & Clinics, Diagnostic Centres), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.
Regional growth and demand
North America is expected to dominate the market during the forecast period in the chronic idiopathic constipation market.
North America held the majority of the market share by revenue for the chronic idiopathic constipation market. The area receives advantages from its high rate of stomach disorders, its rising public knowledge and its advanced medical facilities. The FDA and other regulatory agencies provide their support for new treatment development, which creates market demand for new therapies. The market continues to expand because the ageing population increases, as older people develop CIC at higher rates. The United States is the primary contributor, with significant investments from key players such as AbbVie and Ironwood Pharmaceuticals.
Asia-Pacific is projected to grow the fastest during the forecast period in the chronic idiopathic constipation market.
Asia-Pacific is projected to grow the fastest during the forecast period in the chronic idiopathic constipation market. The area experiences expansion because people move to cities and their eating patterns change, and more people develop diseases caused by their daily routines. The demand for effective CIC treatments in Japan and China is increasing because their governments implement programs that enhance healthcare access and treatment quality. Japan controls the regional market because its people understand gastrointestinal health and the country has a developed pharmaceutical industry. China has emerged as the second-largest market because it is developing its healthcare system while its middle-class population expands
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Chronic Idiopathic Constipation Market.
Ready to lead the Chronic Idiopathic Constipation Market?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the Chronic Idiopathic Constipation Market
- Rising Prevalence of Chronic Idiopathic Constipation
- Growing Ageing Population Increasing Demand
- Shifts Toward OTC and SelfCare Treatments
- Focus on Gut Microbiota and Probiotic Therapies
- Development of Novel Drug Formulations
- Increasing Patient Awareness and Education
- Digital Health and Telemedicine Support for GI Disorders
- Combination Therapies and MultiMechanism Drugs
- Personalised and Precision Treatment Approaches
- Expansion of NonPharmacological Solutions
1. Rising Prevalence of Chronic Idiopathic Constipation
Research studies show that chronic idiopathic constipation affects 10 to 17 percent of the global population which demonstrates higher rates of the condition among elderly people and female patients. The increasing patient population creates a need for effective treatment solutions.
2. Growing Aging Population Increasing Demand
The prevalence of constipation in people who experience gastrointestinal tract physiological changes throughout their aging process. The shifting demographic pattern establishes a continuous requirement for medical solutions which meet the specific needs of elderly patients.
3. Shifts Toward OTC and Self-Care Treatments
Several patients choose to treat their conditions by using over-the-counter laxatives and fibre supplements, and other simple-to-find treatments. The CIC market in the OTC segment experiences growth because of this rising trend.
4. Focus on Gut Microbiota and Probiotic Therapies
The research shows that gut microbiota affects the development of chronic constipation. The market for stomach health products witnesses increased popularity of treatments which use probiotics and prebiotics to establish bacterial equilibrium as viable substitutes or companions to standard medical treatments.
5. Development of Novel Drug Formulations
Pharmaceutical companies now create new treatment alternatives through the development of oral medicines that contain sustained-release components and multiple pathway-targeting drugs. The new developments enable better treatment results through enhanced effectiveness, security and improved treatment for patients.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Chronic Idiopathic Constipation Market.
Empower your strategic planning
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the anti-venom market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 20 Companies Leading the Chronic Idiopathic Constipation Market
- AbbVie Inc.
- Takeda Pharmaceutical Company Ltd.
- Ferring Pharmaceuticals
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Bayer AG
- Johnson & Johnson (Janssen Pharmaceuticals)
- Pfizer Inc.
- GlaxoSmithKline plc (GSK)
- Novartis AG
- Sanofi S.A.
- Eli Lilly and Company
- Bristol Myers Squibb
- Allergan (Part of AbbVie)
- Ironwood Pharmaceuticals, Inc.
- Shire (now part of Takeda)
- Mylan N.V. (now part of Viatris Inc.)
- Otsuka Pharmaceutical Co., Ltd.
- Sandoz (Novartis Division)
- Dr. Reddy’s Laboratories Ltd.
1. AbbVie Inc.
Headquarters: Illinois, USA.
The company was started in 2013, and its recent revenue was ~USD 54–55 billion in the year 2024, and moreover, its Global Operating Sites are in North America, Europe, Asia and other international markets. Its Product Portfolio consists of Chronic idiopathic constipation drugs, gastrointestinal medicines, immunology drugs, and oncology medicines. It is one of the leading global biopharmaceutical companies. Strong presence in gastrointestinal and speciality therapeutic markets.
2. Ironwood Pharmaceuticals, Inc.
Headquarters: Massachusetts, USA.
The company was started in the year 1998, and its recent revenue was USD 400–450 million in the year 2024. Moreover, its Global Operating Sites are in the USA and partnerships in Europe and Asian markets. Its Product Portfolio consists of Chronic idiopathic constipation drugs, gastrointestinal therapies and speciality medicines. It is known for its flagship drug in the constipation treatment segment. Strong focus on gastrointestinal disorder therapies.
3. Synergy Pharmaceuticals Inc.
Headquarters: New York, USA.
The company was started in 2008, and its recent revenue was USD 100–150 million in 2024; moreover, its Global Operating Sites are in the USA with limited international presence. Its Product Portfolio consists of Chronic idiopathic constipation drugs, gastrointestinal therapies and innovative treatment solutions, etc. it is known for developing advanced treatments for digestive disorders. Strong focus on constipation and IBS-related therapies.
4. Bausch Health Companies Inc.
Headquarters: Laval, Quebec, Canada.
The company was started in 1959, and its recent revenue was ~USD 8–9 billion in the year 2024, and moreover, its Global Operating Sites are in North America, Europe, Asia and other international markets. Its Product Portfolio consists of Chronic idiopathic constipation drugs, gastrointestinal medicines, dermatology products and eye health products. It is one of the major global pharmaceutical companies. Strong presence in gastrointestinal and speciality drug markets.
5. Takeda Pharmaceutical Company Limited
Headquarters: Tokyo, Japan.
The company was started in the year 1781, and its recent revenue was USD 30–32 billion in the year 2024, and moreover, its Global Operating Sites are in Japan, the USA, Europe, Asia and other global markets. Its Product Portfolio consists of Chronic idiopathic constipation drugs, gastrointestinal treatments, rare disease medicines, and oncology drugs. it is one of the leading global pharmaceutical companies. Strong presence in gastrointestinal and speciality care segments.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Chronic Idiopathic Constipation Market.
Are you ready to discover more about the Chronic Idiopathic Constipation Market?
The report provides an in-depth analysis of the leading companies operating in the global Chronic Idiopathic Constipation market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardised format that includes:
Company Profile
- AbbVie Inc.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Takeda Pharmaceutical Company Ltd.
- Ferring Pharmaceuticals
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Bayer AG
- Johnson & Johnson (Janssen Pharmaceuticals)
- Pfizer Inc.
- GlaxoSmithKline plc (GSK)
- Novartis AG
- Sanofi S.A.
- Eli Lilly and Company
- Bristol Myers Squibb
- Allergan (Part of AbbVie)
- Ironwood Pharmaceuticals, Inc.
- Shire (now part of Takeda)
- Mylan N.V. (now part of Viatris Inc.)
- Otsuka Pharmaceutical Co., Ltd.
- Sandoz (Novartis Division)
- Dr. Reddy’s Laboratories Ltd.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Chronic Idiopathic Constipation Market.
Conclusion
The global chronic idiopathic constipation market size is expected to grow at a compound annual growth rate (CAGR) of 6.1%, from USD 6.28 billion in 2024 to USD 3.1 billion by 2035. Global market expansion is driven by rising cases of chronic idiopathic constipation, growing awareness, an ageing population, technological advancement, and demand for over-the-counter solutions. North America held the majority of the market share by revenue for the browser market. The area receives advantages from its high rate of stomach disorders, its rising public knowledge and its advanced medical facilities. Asia-Pacific is projected to grow the fastest during the forecast period in the browser market. The area experiences expansion because people move to cities and their eating patterns change, and more people develop diseases caused by their daily routines.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?